Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00346983 · ClinicalTrials.gov registry record · Phase 1
Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics
A Phase 1 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00346983: Clinical Trial Phase 1 study, sponsored by Johns Hopkins University.
NCT00346983 is a Phase 1 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00346983, a Phase 1 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This research is being conducted to look at the effects of an intraocular drug (pegaptanib, also called Macugen) for the treatment of swelling in the retina (the light sensitive tissue in the back of the eye) that often occurs following cataract surgery in patients with diabetic eye disease. Swelling in the retina can lead to blurry vision, and Macugen may reduce this swelling. Eyedrops that decrease inflammation also may help to stop some of the swelling. We are testing this drug (pegaptanib) to see if it can decrease swelling in the retina and improve vision in patients with diabetes who are having cataract surgery.
Interventions
- DRUG Control
- DRUG Pegaptanib sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00346983
The ClinicalTrials.gov registry entry for NCT00346983 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT00346983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00346983 about?
NCT00346983 is a clinical study titled "Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics". This research is being conducted to look at the effects of an intraocular drug (pegaptanib, also called Macugen) for the treatment of swelling in the retina (the light sensitive tissue in the back of the eye) that often occurs following cataract surgery in patients with diabetic eye disease. Swellin...
What is the current status of trial NCT00346983?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2006-06. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00346983?
The interventions under investigation include: Control (DRUG), Pegaptanib sodium (DRUG).
Who is sponsoring clinical trial NCT00346983?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.